Navigation Links
Sb, Urine

ProductsSb, Urine
Company ARUP Laboratories
Item Sb, Urine
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Clinitek 500 Urine Chemistry Analyzer
2. Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
3. Chemstrip 101 Urine Analyzer
4. Clinitek Atlas Automated Urine Chemistry Analyzer (Carousel)
5. Urisys 1100 Urine Analyzer
6. Criterion™ II Urine Analyzer
7. DiaScreen 50 Urine Chemistry Analyzer
8. FSH Home Menopause Test Midstream (Urine)
9. FSH Home Menopause Test Device (Urine)
10. Acon One Step Ovulation Test Device (Urine)
11. One Step LH Urine Ovulation Test
TAG: Urine
EL301 Microwell Strip Reader is a portable, rugged, single/dual wavelength photometer designed to measure and interpret the absorbances of microwell strip assays.
NRTL and CE certified microstrip reader. Stat fax 303 plus an automatic strip transportation. Easy to use with step-by-step prompting and on-board graphics printer. log-logit mode and other programmi
Lab-Incubator/Shaker.
The Millennium 2000 is a unique microprocessor controlled shaking incubator that accommodates up to 4 microplates in either 96 or 384 well format. Speed, temperature and time are programmed via the c
Medicine Products:
(Date:12/2/2008)... groups of immigrants in Oslo. Compared with Norwe...nces are seen for risk factors and actual diseases... Institute of Public Health. Five of the largest i...the ethnic Norwegian population. The report was co... , The five immigrant groups in this study come ...
(Date:12/2/2008)...l assault are unsettling; the Department of Justic...he victim of attempted or actual sexual assault du...ers from two universities, including the Universit... are unaware of drug-facilitated sexual assault an... including leaving drinks unattended. , "These ...
(Date:12/2/2008)...r ranks No. 1 nationwide for the speed with which ...gioplasty, according to the National Cardiovascula... (Vocus) December 2, 2008 -- UCSF Medical Center r...rt attack patients are treated using balloon angio...ata Registry (NCDR). Cardiac balloon angioplasty ...
(Date:12/2/2008)...Today, advocates for teen,dating violence educati...Liz,Claiborne Inc. to launch ,MADE, -- Moms and D...and Chris Burke, educators and parents of Lindsay ...riend, are joining efforts with Liz,Claiborne Inc...that will,consist of parents, teachers and concer...
Breaking Medicine News(10 mins):Health News:Large health differences between population groups in Norway 2Health News:Large health differences between population groups in Norway 3Health News:Large health differences between population groups in Norway 4Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 3Health News:UCSF Medical Center Leads Nation in ER Heart Attack Care 2Health News:UCSF Medical Center Leads Nation in ER Heart Attack Care 3Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 2Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 3
...ssociation between the level of sex hormones and a...eptors for the female hormones estrogen and proges...eptors are the eyes and ears of the cells, receivi... hormones. Estrogen and progesterone stimulate gro...
...acupuncture can help those suffering from arthriti...rrent multi-location trial included 570 patients a...articipants were placed in three groups. One hundr...ure, 191 underwent sham acupuncture, and 189 follo...
...ns are currently performed among the diabetic popu... blood vessels in the retinas of about 900 diabeti... before age 30. All were followed for 20 years to ...ight relate to subsequent need for an amputation. ...
... of countries where iodine deficiency is a public ... on a new global report on iodine status.// The si...ed well. The number of countries where iodine defi...reduced to 54 in 2003, from 110 in 1993. "Iodine d...
Other Medicine News:Health News:WHO hopes to wipe away Iodine deficiency diseases by 2005 2
(Date:12/2/2008)...ll., Dec. 2 Horizon Therapeutics, ... today announced that two pivotal,Phase 3 trials ...ate, HZT-501,met all primary endpoints. HZT-501,...uct containing ibuprofen and famotidine, demonstra...incidence of non-steroidal,anti-inflammatory drug...
(Date:12/1/2008)..., Dec. 1 TargeGen has announced th...rom a multi-center, US-based clinical,trial of TG...been scheduled at,the 2008 American Society of He...presentation are as follows:, Title: ...ailable, JAK2-Selective In...
(Date:12/1/2008)...tinence is still the best policy , , ROCHE...ew study from Mayo Clinic finds the use of the dru...olic hepatitis, an acute inflammation of the liver...esults of the study are published in the December ...rnal.org/ ). , , VIDEO ALERT: Additional a...
(Date:12/1/2008)..., Dec. 1 Vical Incorpora...of a $1.0 million milestone payment from Merck &am...f a Phase I clinical trial of an investigational p...ccine is based on Vical,s DNA gene delivery techno...ptase (hTERT). hTERT is the subject of separate li...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 1Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 2Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 3Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 4Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 5Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 6Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 7Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 8Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 9Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 10Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 7705 1Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 7705 2Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 1Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 2Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 3Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 1Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 2Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 3Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 4Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 5Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 6Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 7Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 8Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 9Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 10Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 11Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 12Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 13Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 14
... - TransPharma Medical,Ltd., a specialty pharmaceu...rcialization of drug products utilizing a propriet...nnounced today,promising results of its phase I cl...okinetic profile of its ViaDerm-hPTH (1-34),produc... repeated dose application, parallel group study w...
... to Show That Extended,Thromboprophylaxis Reduces ...atistically Significant 44% , PARIS, July 8, 2007 ...today the results of the EXCLAIM (EXtended CLinica...dy, which showed,the benefit of extended prophylax...bility by demonstrating the superiority of 5 weeks...
Other Medicine Technology:TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6